Topics:
Medical Oncology • Myeloma
In a patient with multiple myeloma who cannot tolerate lenalidomide or bortezomib due to GI toxicity, what regimen would you choose for next-line therapy?
Is there evidence for daratumumab-based doublet regimens?
Would your choice differ based on the patient's transplant eligibility?
Answer from: Medical Oncologist at Academic Institution
Often, lowering the dose of lenalidomide and/or bortezomib does help. If the patient absolutely cannot tolerate at any dose levels, then I would do Daratumumab based therapy. Start with Daratumumab/dex; if it's tolerable, one can add pomalidomide. Intolerance to lenalidomide does not mean intoleranc...
Sign in or Register to read more